Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics Announces Pricing of Public Offering of Common Stock

Business Wire September 8, 2016

Sage Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire September 7, 2016

Sage Receives FDA Breakthrough Therapy Designation for SAGE-547 for the Treatment of Postpartum Depression

Business Wire September 6, 2016

Sage Therapeutics and Collaborators Announce Publication Highlighting Epidemiology and Burden of Illness for Super-Refractory Status Epilepticus in Journal of Medical Economics

Business Wire August 30, 2016

Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update

Business Wire August 9, 2016

Sage Therapeutics to Present at the Canaccord Genuity 36th Annual Growth Conference

Business Wire August 3, 2016

Sage Therapeutics to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016

Business Wire August 2, 2016

Sage Appoints Geno Germano to Company's Board of Directors

Business Wire July 19, 2016

Mid-Afternoon Market Update: Dow Jumps 140 Points; Imperva Shares Slide Following Reduced Q2 Outlook

Benzinga.com  July 12, 2016

12 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  July 12, 2016

Benzinga's Volume Movers

Benzinga.com  July 12, 2016

Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

Benzinga.com  July 12, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  July 12, 2016

Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression

Business Wire July 12, 2016

Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics

PR Newswire June 27, 2016

Goldman Sachs: 3 Options Trades To Make Ahead Of The Brexit Vote

Benzinga.com  June 16, 2016

Sage Reports Positive Top-line Results from Phase 1 Clinical Program of SAGE-217

Business Wire June 7, 2016

Sage Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference

Business Wire June 1, 2016

Sage Therapeutics Announces Completion of Enrollment for Phase 2 Proof-of-Concept Trial of SAGE-547 in Severe Postpartum Depression

Business Wire May 26, 2016

Sage Therapeutics Announces First Quarter 2016 Financial Results

Business Wire May 5, 2016